Growth factors activate multiple beneficial signaling pathways including those involved in cell survival, proliferation and mobilization of progenitor cells. However, native growth factors have poor drug-like properties on their own. We are engineering Smart Growth Factors (SGFs), with improved pharmacokinetics (PK), pharmacodynamics (PD), and accumulation to enhance their drug-like properties for optimization as cardioprotective therapeutics.
- Computational modeling: Model simulations inform protein engineering and molecule design.
- Protein engineering: Modify native GFs by fusing them to partner proteins with extended PK and targeting properties.
- In vitro screening: Screen SGF potency and targeting arm affinity for specific cell type of interest.
- In vivo testing: Optimize leads by evaluating SGF efficacy in animal disease models.